November 21, 2022, Intelligence: Late-Breaking Lab News

In yet another employment ripple from the pandemic, a group of more than 75 pathologists penned a letter to Congress urging lawmakers to retain the option for remote diagnostic work. In the letter, which appeared in the Oct. 20 issue of Nature, the pathologists wrote, “During the COVID-19 pandemic of the past 30 months, one of the early regulatory exemptions enabled the (optional) use of remote work in clinical laboratories and pathology.” The group asked Congress to permanently amend the Clinical Laboratory Improvement Amendments of 1988 to explicitly allow pathologists to work remotely. Until then, the authors asked federal health officials to keep pandemic-related exemptions in place for remote diagnostics work.

MORE ON: Lab Lobbying

Pathologists have been busy in the last few months attempting to persuade members of Congress to take action that would help clinical labs and practice groups. Back in August, a group of 290 laboratory directors and pathologists, many from academic medical centers, wrote to lawmakers to voice concerns about potential new regulations that would adjust oversight of laboratory-developed tests (LDTs). The Dark Report noted the influence this group wielded.


In new research that portends continued staffing shortages among anatomic pathologists, management consulting firm Bain & Company revealed that 25% of clinicians are considering changing careers. Bain’s Frontline of Healthcare study polled 573 physicians, nurses, and advanced practice providers. The most-cited reason? Burnout. “U.S. clinicians have been bearing the brunt of a brutal environment over the past two years,” Bain noted. “As clinical acuity and medical uncertainty rose with the pandemic, providers’ financial health steadily slipped, and labor challenges mounted.” 


Matt Sause, President and CEO of Roche Diagnostics North America, will become CEO of Roche Diagnostics on Jan. 1. Aside from brief stints at Genentech and Gilead Sciences from 2018 to 2019, Sause has worked at Roche for two decades. 

• Quantum-Si of Guilford, Conn., appointed Jeff Hawkins as CEO. Hawkins previously held executive positions at Truvian Sciences, Illumina, GenMark, Hologic, Third Wave Technologies, and Abbott Laboratories.

• Indiana University School of Medicine named Michael Feldman, MD, PhD, as Chair of the Department of Pathology and Laboratory Medicine effective Feb. 1. Feldman is currently Vice Chair of Clinical Services in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia and also teaches at the school.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.